IFNA13, interferon alpha 13, 3447

N. diseases: 646; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE In conclusion, the Fib-4 score may predict early hematological adverse effects in HCV-infected patients on IFN-based triple therapy. 30657408 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression disease BEFREE Sessions included: IFN-λ Biology, Therapy and Genetic Variation; IFN-λ and Hepatitis C Virus Infection; IFN-λ in Other Infections; and IFN-λ-Hepatic Fibrosis and Cancer. 30998425 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE Variants of rs2111485 and rs1990760 at <i>IFIH1</i> may be associated with spontaneous HCV clearance in Chinese Han population, but have no effect on HCV clearance induced by IFN-<i>α</i>. 31539314 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE In uremic subjects, polymorphisms within the IFN-λ chromosomal region associate with spontaneous HCV clearance, similarly like in the non-uremic population. 30027841 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE The Brazilian Public Health Service provides freely αPEG-IFN to treat patients infected with HCV. 30243981 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE By demonstrating that IFN-λ variation leaves a large footprint on the viral proteome, we provide evidence of pervasive viral adaptation to innate immune pressure during chronic HCV infection. 31478832 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE These observations present an apparent conundrum-when and how does a presumably good IFN, with anti-HCV activity, interfere with the ability to clear HCV? 31241411 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE Genetic variants in the IFN-λ region have also been associated with hepatic inflammation and fibrosis from various etiologies, however, alleles that are linked with improved HCV clearance associates with worse inflammation and fibrosis. 31161939 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Treatment-emergent depression is a common complication in patients with chronic hepatitis C virus (HCV) infection undergoing antiviral combination therapy with IFN-α and ribavirin. 31332697 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE An interferon λ4 gene (IFNL4) knockout allele (rs368234815; TT) is associated with spontaneous and IFN-α-dependent cure of hepatitis C virus infection. 30289470 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Based on these findings, ribavirin-induced anti-RR autoantibody seems to be associated with a more frequent nonresponse to IFN-<i>α</i>/ribavirin therapy with a significant higher HCV viral load. 31081724 2019
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE DAA therapy causes far fewer adverse reactions compared with IFN therapy and has been reported to be highly effective in treating HCV infection in hemodialysis patients. 30041215 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE This study aimed to determine the association of rs2430561 and rs4073 polymorphisms in the Interferon gamma (IFN-ɤ) and Interleukin 8 (IL-8) genes, respectively, with hepatitis C virus-related oral lichen planus and disease severity. 30290294 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4. 29753376 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE We employed three virus derivatives-wild-type Jc1, interferon (IFN)-resistant virus IR, and high-replicative-fitness virus P100-in order to explore additional IFN-α-related virus inhibition mechanisms. pDCs inhibited HCV infectivity and replication and produced IFN-α. 30232187 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Chronic HCV and HBV infection and IFN-based HCV therapy were not associated with DM. 29901821 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Peg-IFN/ribavirin was effective and tolerable for thalassemic HCV patients. 29097076 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Finally, EVs from patients with hepatitis C exhibited long-lasting antiviral activities during IFN therapy as well. 29706960 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE We undertook a longitudinal prospective study of 33 individuals with chronic HCV treated with combination pegylated IFN-α, ribavirin, and telaprevir/boceprevir. 29263212 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE Ten patients with HCV (genotype 1) were vaccinated with monocyte-derived DCs, generated in the presence of IFN-α (IFN-DCs) and pulsed with recombinant HCV Core and NS3 proteins. 29164490 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE HCV-infected subjects receiving OST did not experience similar PRO improvements with IFN-containing therapy, suggesting that IFN-based therapy may be less suitable for this vulnerable population. 29293991 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE This prospective, randomized, multicenter study indicated that FLV had no add-on effect when given with SMV/Peg-IFN/RBV combination therapy for genotype 1b HCV-infected patients. 28722780 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE The aim of the study was to correlate the effects of host cytokine single nucleotide polymorphisms of TNF-α (-308 A/G) and IFN-γ (+874 A/T) in spontaneous or IFN induced treatment response in the HCV infected thalassemic individuals. 29196132 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker disease BEFREE However, little information is available about the effect of alcohol on interferon-lambda (IFN-λ, type III IFN), a novel candidate for development of therapy for HCV infection. 29446489 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation disease BEFREE Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population. 30383478 2018